Beyond a "Red Meat Allergy": What 2,500+ Patient Surveys Suggest About Alpha-gal Syndrome, Misdiagnosis, and Long-Term Symptoms

Patient-Reported Data. Real Impact.

Across the United States, awareness of Alpha-gal syndrome (AGS) is finally beginning to grow.

Several states now require some form of Alpha-gal case reporting, including:

• Arkansas

• Delaware

• Iowa

• Kentucky

• Massachusetts

• Nebraska

• New Jersey

• North Dakota

• Oklahoma

• South Carolina

• Tennessee

• Virginia

• West Virginia

This represents important progress.

But based on more than 2,500 U.S. patient-reported survey responses collected through TickBiteData.com, a larger problem remains:

Many patients are still being misdiagnosed.

And for a growing number of respondents, the condition they describe extends far beyond what most people — and many healthcare professionals — currently understand as simply a “red meat allergy.”

A Consistent Pattern Across States

Among the top reporting states in our survey dataset, reported misdiagnosis rates consistently exceeded 60%.

State	Reported Misdiagnosis Rate
Arkansas	71.7%
Virginia	66.4%
North Carolina	65.6%
Oklahoma	64.6%
Kansas	64.6%
Missouri	64.1%
Indiana	64.0%
Kentucky	62.2%
Tennessee	61.8%
Illinois	61.5%

These findings are notable because the consistency appears nationwide.

This is not isolated to one physician group, one healthcare network, or one region.

The same themes appear repeatedly across thousands of patient experiences:

• gastrointestinal symptoms

• neurological symptoms

• delayed reactions after eating

• years of confusion

• anxiety diagnoses

• repeated emergency room visits

• long diagnostic delays

The most common term repeatedly appearing in patient narratives?

“Anxiety.”

“They Told Me It Was Anxiety.”

One of the strongest and most concerning trends in the survey data is how often patients report being told their symptoms were psychological before being evaluated for Alpha-gal syndrome or other tick-borne illness.

The following quotes are reproduced directly from patient survey submissions.

“Doctor just pushed it off as anxiety, just wanted to medicate for anxiety and depression. I had to beg for an emergency Epi-pen.”

“I was diagnosed incorrectly several times with stomach ulcers, anxiety, panic disorder, idiopathic urticaria, later idiopathic anaphylaxis.”

“PCP diagnosed anxiety and prescribed BH meds. Neurological symptoms increased in severity over the next 6 months.”

“My dr thought I was crazy. I asked for an alpha gal test and she reluctantly ordered one.”

The data suggest many patients are entering the healthcare system with:

• abdominal pain

• nausea

• diarrhea

• dizziness

• rapid heart rate

• flushing

• neurological symptoms

• insomnia

• panic-like episodes

• unexplained inflammation

Yet many report never being evaluated for Alpha-gal syndrome until years later.

The Neurological Patterns Cannot Be Ignored

Public discussion surrounding Alpha-gal syndrome still largely focuses on allergy and anaphylaxis.

However, the patient-reported symptom patterns in this dataset repeatedly suggest something broader may be occurring in at least a subset of patients.

The most commonly reported neurological symptoms in the dataset include:

• Brain fog

• Mental fatigue

• Headaches

• Dizziness

• Anxiety-like symptoms

• Tremors

• Sleep disturbances

Many respondents also report persistent:

• muscle cramps

• arthritis or joint pain

• neuropathy-like symptoms

• weakness

• inflammation

• mood changes

Importantly, many patients report these symptoms continuing even after strict avoidance of mammalian foods.

This raises difficult but necessary questions:

Are some patients experiencing additional immune or inflammatory processes after tick exposure?

Could co-infections or other tick-borne illnesses be contributing?

Are current clinical frameworks too narrowly focused on food allergy alone?

These are research questions that deserve serious scientific investigation.

Tick-Borne Illness Testing Remains Fragmented

Another major issue repeatedly raised by respondents is the complexity of tick-borne disease testing.

Many patients assume there is a single comprehensive “tick-borne illness test.”

There is not.

Instead, patients are often required to undergo numerous individual tests for:

• Alpha-gal syndrome

• Lyme disease

• Ehrlichiosis

• Babesiosis

• Rocky Mountain spotted fever

• Bartonella

• Anaplasmosis

• and other region-specific infections

This fragmented approach creates significant barriers:

• delayed diagnosis

• incomplete evaluations

• financial burden

• repeated specialist visits

• missed co-infections

There should be stronger discussion surrounding development of comprehensive tick-borne illness panels that allow clinicians to evaluate multiple potential conditions simultaneously.

Cross-Contamination and Mammalian Products Remain Poorly Understood

Another major pattern in the survey data involves reactions to cross-contamination and mammalian-derived ingredients beyond traditional meat consumption.

Many respondents report reactions associated with:

• medications containing gelatin

• mammalian-based additives

• hospital-administered products

• cross-contaminated food preparation

• supplements

• hygiene products

Several patients specifically described healthcare settings where providers were unaware that mammalian-derived ingredients could trigger reactions.

One respondent wrote:

“No explanation about cross contamination or complications of medications...”

Another respondent reported:

“Medicine given at the hospital has also triggered anaphylaxis, regardless of me providing the information that I have alphagal.”

This suggests there may still be substantial awareness gaps surrounding non-food mammalian exposures.

International Participation Suggests a Broader Global Issue

TickBiteData survey participation currently includes respondents from:

• Argentina

• Australia

• Belgium

• Canada

• Cuba

• France

• Italy

• Lebanon

• Malawi

• South Africa

• Sweden

• United Kingdom

• United States

International respondents also report significant rates of misdiagnosis and delayed recognition, suggesting the need for broader awareness and education surrounding Alpha-gal syndrome globally.

The tick species may differ by country.

But many patients report remarkably similar symptom patterns.

A Personal Reflection After Speaking With AGS Researchers

Recently, I had the opportunity to speak with Dr. Scott Commins, one of the most recognized researchers in Alpha-gal syndrome.

The conversation was fascinating and informative.

However, one thing became increasingly clear to me during that discussion — and through conversations with other healthcare professionals — is that many experts remain heavily focused on the allergy component of Alpha-gal syndrome itself.

That focus is understandable. But the patient experiences being reported through this dataset often extend beyond what many people traditionally associate with an allergy.

Patients repeatedly describe:

• chronic neurological symptoms

• inflammatory symptoms

• muscle cramping

• arthritis-like pain

• long-term quality of life decline

• ongoing symptoms despite dietary avoidance

This does not mean causation has been scientifically established. But it does mean the questions deserve to be asked. And patients deserve to be heard.

Why TickBiteData Exists

TickBiteData was created because thousands of patients felt their experiences were not being fully captured.

The goal is not to replace physicians, researchers, or public health agencies.

The goal is to collect large-scale patient-reported observational data that may help:

• identify patterns

• improve awareness

• reduce diagnostic delays

• support future research

• highlight underrecognized symptom clusters

• encourage broader scientific investigation

Patient-reported data alone does not establish causation.

But historically, patient-reported trends have often helped identify important questions long before medicine fully understood the answers.

The Questions We Believe Deserve Further Investigation

Based on recurring patterns in the dataset, several questions warrant further study:

• Why are neurological symptoms reported so frequently?

• Why are so many patients initially diagnosed with anxiety disorders?

• Are some patients experiencing overlapping tick-borne illnesses?

• Why do many patients continue reporting symptoms despite dietary avoidance?

• Are mammalian-derived medical products underrecognized triggers?

• Why does diagnostic delay remain so common even in high-awareness states?

• Could earlier intervention after tick exposure improve outcomes in certain cases?

These are not fringe questions.

They are questions emerging repeatedly from thousands of patient experiences.

Final Thoughts

Alpha-gal syndrome is currently classified as an allergy.

But many patients describe a lived experience that feels far more complex.

The growing body of patient-reported data suggests there may be broader systemic, neurological, inflammatory, and quality-of-life components that deserve more scientific attention.

Medicine advances by asking difficult questions.

And right now, patients across the world are asking them.

About TickBiteData

TickBiteData.com is an independent patient-reported data initiative focused on collecting observational survey data related to Alpha-gal syndrome and tick-borne illness experiences.

The project aims to support awareness, future research, public health discussion, and improved understanding of real-world patient experiences.

Patient-reported survey data should not be interpreted as establishing clinical causation or replacing medical advice.

Visit: www.TickBiteData.com